|
|
29 April 2019 |
Advanced Medical Solutions Group plc
(“AMS”, the “Company” or the “Group”)
Director/PDMR Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that the Trust which manages the Deferred Share Bonus Plan (“DSB”) on behalf of the employees of AMS has purchased ordinary shares of 5 pence each (“Ordinary Shares”) on 29 April 2019, at a price of 330p on behalf of Chris Meredith and Eddie Johnson, who are both Directors and PDMRs, as part of the DSB and, under the terms of the DSB, these shares will be held in trust on their behalf.
Following these transactions the beneficial ownership of Chris Meredith and Eddie Johnson are as follows:
|
Director/PDMR |
Date purchased |
Shares purchased |
Resultant holding |
% of issued share capital |
|
Chris Meredith Chief Executive Officer |
29 April 2019 |
10,182 |
1,494,577 |
0.7% |
|
Eddie Johnson Chief Financial Officer |
29 April 2019 |
3,847 |
59,426 |
0.028% |
Advanced Medical Solutions Group plc further announces that it was notified on 29 April 2019 that Chris Meredith, who is a Director and PDMR, following the end of the holding period, exercised 32,638 options from the Deferred Annual Bonus Plan (DAB). Mr Meredith elected to receive an additional 369 dividend shares which were earned during the 3 year holding period under the terms of the scheme.
Mr Meredith subsequently sold 33,007 Ordinary Shares of 5p each on 29 April 2019 at a share price of 330p per Ordinary Share. As a result of these transactions Mr Meredith’s beneficial interest in the Company has not changed.
Overall Holding
|
PDMR |
Holding prior to exercise (including DSB purchase) |
Number of shares exercised |
Dividend Shares received |
Number of shares sold |
Sale price (p) |
Resultant holding |
% of issued share capital |
|
Chris Meredith |
1,494,577 |
32,638 |
369 |
33,007 |
330p |
1,494,577 |
0.7% |
Advanced Medical Solutions Group plc also announces that on 24 April 2019, the Board, following a recommendation from the Remuneration Committee, granted new share options to the following Directors under the Advanced Medical Solutions Deferred Annual Bonus Plan (the ‘2014 DAB’).
This award is in respect of the part of their bonus that the Directors and PDMRs are compulsorily required to defer for the 2018 financial year. These options vest at the end of three years. Details of the current DAB holdings of the Directors/PDMRs following these awards and the exercise of DAB options by Chris Meredith are shown below:
|
Director/PDMR |
Options prior to grant/exercise |
Options granted |
Options exercised |
Resultant holding |
|
Chris Meredith Chief Executive Officer |
77,756 |
12,859 |
32,638 |
57,977 |
|
Eddie Johnson Chief Financial Officer |
20,333 |
2,209 |
– |
22,542 |
Advanced Medical Solutions Group plc further announces that on 24 April 2019, the Board, following a recommendation from the Remuneration Committee, granted new share options to the following Directors/PDMRs under the Advanced Medical Solutions Long Term Incentive Plan (the ‘LTIP’). The vesting period of these options is subject to certain performance criteria over a three year period.
|
Director/PDMR |
Options prior to grant |
Options granted |
Resultant holding |
|
Chris Meredith Chief Executive Officer |
476,482 |
182,510
|
658,992
|
|
Eddie Johnson Chief Financial Officer |
105,739
|
38,783
|
144,522
|
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Chris Meredith |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Purchase of 10,182 Ordinary Shares as part of the Deferred Share Bonus Plan on 29 April 2019 at a price of 330p |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 29/04/2019 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Eddie Johnson |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Purchase of 3,847 Ordinary Shares as part of the Deferred Share Bonus Plan on 29 April 2019 at a price of 330p |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 29/04/2019 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Chris Meredith |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Exercise of 32,638 shares from the Deferred Annual Bonus Plan · Award of 369 Dividend Shares from the Deferred Annual Bonus Plan · Sale of 33,007 Ordinary Shares of 5p |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: 33,007 Aggregated price: £3.300 |
||||
|
e) |
Date of the transaction: 29/04/2019 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Chris Meredith |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Grant of 182,510 options under the Advanced Medical Solutions Long Term Incentive Plan on 24 April 2019 · Grant of 12,859 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 24 April 2019 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 24/04/2019 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Eddie Johnson |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Grant of 38,783 options under the Advanced Medical Solutions Long Term Incentive Plan on 24 April 2019 · Grant of 2,209 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 24 April 2019 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 24/04/2019 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
-End –
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: 44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer |
|
|
|
|
|
Consilium Strategic Communications |
Tel: 44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Matthew Neal / Nicholas Brown / Olivia Manser |
AMS@consilium-comms.com |
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: 44 (0) 20 7597 5970 |
|
Daniel Adams / Patrick Robb / Gary Clarence |
|
About Advanced Medical Solutions Group plc – see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include tissue adhesives, sutures, biosurgical devices, internal sealants, silver alginates, alginates and foams, which it markets under its brands; LiquiBand®, LiquiBand® Fix 8™, RESORBA® and ActivHeal® as well as supplying under white label.
AMS‘s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 630 employees. For more information, please see www.admedsol.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHBLGDSSDDBGCC